Eli Lilly Total Liabilities 2010-2024 | LLY

Eli Lilly total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Eli Lilly total liabilities for the quarter ending September 30, 2024 were $61.286B, a 31.49% increase year-over-year.
  • Eli Lilly total liabilities for 2023 were $53.143B, a 37.27% increase from 2022.
  • Eli Lilly total liabilities for 2022 were $38.714B, a 2.36% decline from 2021.
  • Eli Lilly total liabilities for 2021 were $39.651B, a 2.83% decline from 2020.
Eli Lilly Annual Total Liabilities
(Millions of US $)
2023 $53,143
2022 $38,714
2021 $39,651
2020 $40,808
2019 $36,587
2018 $32,999
2017 $33,313
2016 $24,725
2015 $20,979
2014 $20,920
2013 $17,608
2012 $19,625
2011 $20,124
2010 $18,589
2009 $17,936
Eli Lilly Quarterly Total Liabilities
(Millions of US $)
2024-09-30 $61,286
2024-06-30 $58,239
2024-03-31 $51,046
2023-12-31 $53,143
2023-09-30 $46,608
2023-06-30 $43,665
2023-03-31 $41,868
2022-12-31 $38,714
2022-09-30 $37,296
2022-06-30 $38,404
2022-03-31 $37,457
2021-12-31 $39,651
2021-09-30 $40,233
2021-06-30 $41,146
2021-03-31 $39,739
2020-12-31 $40,808
2020-09-30 $38,950
2020-06-30 $37,695
2020-03-31 $37,906
2019-12-31 $36,587
2019-09-30 $34,431
2019-06-30 $35,809
2019-03-31 $35,442
2018-12-31 $32,999
2018-09-30 $30,474
2018-06-30 $30,738
2018-03-31 $29,768
2017-12-31 $33,313
2017-09-30 $28,050
2017-06-30 $26,777
2017-03-31 $23,521
2016-12-31 $24,725
2016-09-30 $21,975
2016-06-30 $21,819
2016-03-31 $19,662
2015-12-31 $20,979
2015-09-30 $21,064
2015-06-30 $21,331
2015-03-31 $20,707
2014-12-31 $20,920
2014-09-30 $16,966
2014-06-30 $17,024
2014-03-31 $16,408
2013-12-31 $17,608
2013-09-30 $17,070
2013-06-30 $17,990
2013-03-31 $17,345
2012-12-31 $19,625
2012-09-30 $18,264
2012-06-30 $17,505
2012-03-31 $17,416
2011-12-31 $20,124
2011-09-30 $17,984
2011-06-30 $18,502
2011-03-31 $17,761
2010-12-31 $18,589
2010-09-30 $17,499
2010-06-30 $17,488
2010-03-31 $16,736
2009-12-31 $17,936
2009-09-30 $17,223
2009-06-30 $18,372
2009-03-31 $18,872
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $692.744B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94